News >

Expert Shares Treatment Updates for Neuroendocrine Tumors

Danielle Bucco
Published: Tuesday, Apr 10, 2018

Emily K. Bergsland, MD

Emily K. Bergsland, MD
The incidence of neuroendocrine tumors (NETs) has increased 5-fold over the past 30 years, making it the second most prevalent diagnosis in gastrointestinal (GI) malignancies, explains Emily K. Bergsland, MD, a professor of medicine at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center.1

“Resection of the disease continues to be a treatment for patients with well-differentiated gastroenteropancreatic (GEP)- NETs and is still conducted in more than 70% of patients with these tumors. However, the recurrence rate for patients who received a resection is 100% at 10 years, changing the treatment paradigm as this was previously considered a curative therapy,” said Bergsland in her presentation at the 2018 OncLive® State of the Science SummitTM on Gastrointestinal Cancers.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication